Search Options Stock News and Analysis from Schaeffer's

Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years

https://www.schaeffersresearch.com/content/news/2024/12/19/vertex-pharmaceuticals-stock-heads-for-worst-day-in-4-years

12/19/2024 11:23 AM

Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study. ...

Biotech Roundup: 3 Stocks to Watch

https://www.schaeffersresearch.com/content/news/2024/12/11/biotech-roundup-3-stocks-to-watch

12/11/2024 3:35 PM

Most recently in the ever-growing biotech industry, investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and D...

2 Biotech Stocks Driving the Nasdaq Today

https://www.schaeffersresearch.com/content/news/2024/04/11/2-biotech-stocks-driving-the-nasdaq-today

4/11/2024 1:41 PM

The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today. Digging deeper, Alpine Immune Sciences Inc (NASDAQ:ALPN) is soaring to eigh...

Potential Stock Market Trends to Monitor Next Year

https://www.schaeffersresearch.com/content/bgs/2023/12/27/potential-stocks-market-trends-to-monitor-next-year

12/27/2023 3:36 PM

Subscribers to Chart of the Week received this commentary on Sunday, December 24. Taylor Swift may have won Time Person of the Year, but in the investing world, artificial intelligence (AI) was the ...

Crispr Therapeutics Stock Sinks Despite FDA Approval

https://www.schaeffersresearch.com/content/options/2023/12/11/crispr-therapeutics-stock-sinks-despite-fda-approval

12/11/2023 3:31 PM

Crispr Therapeutics AG ( NASDAQ:CRSP) stock is down 7.2% to trade at $59.89 at last check, despite its gene therapy treatment for sickle cell disease in partnership with Vertex (VRTX) last week receiv...

PEOPLE ALSO SEARCH FOR

-intraday-options-activity